Comprehensive analysis reveals potential therapeutic targets and an integrated risk stratification model for solitary fibrous tumors

• Published in: Nature communications 2023-11, Vol.14 (1), p.7479-7479, Article 7479
• Main Authors: Zhang, Renjing, Yang, Yang, Hu, Chunfang, Huang, Mayan, Cen, Wenjian, Ling, Dongyi, Long, Yakang, Yang, Xin-Hua, Xu, Boheng, Peng, Junling, Wang, Sujie, Zhu, Weijie, Wei, Mingbiao, Yang, Jiaojiao, Xu, Yuxia, Zhang, Xu, Ma, Jiangjun, Wang, Fang, Zhang, Hongtu, Ma, Peiqing, Zhu, Xiaojun, Song, Guohui, Sun, Li-Yue, Wang, De-Shen, Wang, Feng-Hua, Li, Yu-Hong, Santagata, Sandro, Li, Qin, Feng, Yan-Fen, Du, Ziming
• Format: Article
• Language: English
• Subjects: 45/22; 45/23; 45/77; 631/67/1798; 631/67/68; 631/67/70; 82/51; 82/80; CD163 antigen; Humanities and Social Sciences; Macrophages; Medical treatment; Metastases; multidisciplinary; PD-L1 protein; Risk factors; Science; Science (multidisciplinary); Therapeutic targets; TOR protein; Tumors
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-023-43249-4

Solitary fibrous tumors (SFTs) are rare mesenchymal tumors with unpredictable evolution and with a recurrence or metastasis rate of 10-40%. Current medical treatments for relapsed SFTs remain ineffective. Here, we identify potential therapeutic targets and risk factors, including IDH1 p.R132S, high PD-L1 expression, and predominant macrophage infiltration, suggesting the potential benefits of combinational immune therapy and targeted therapy for SFTs. An integrated risk model incorporating mitotic count, density of Ki-67+ cells and CD163+ cells, MTOR mutation is developed, applying a discovery cohort of 101 primary non-CNS patients with negative tumor margins (NTM) and validated in three independent cohorts of 210 SFTs with the same criteria, and in 36 primary CNS SFTs with NTM. Compared with the existing models, our model shows significantly improved efficacy in identifying high-risk primary non-CNS and CNS SFTs with NTM for tumor progression.Our findings hold promise for advancing therapeutic strategies and refining risk prediction in SFTs. Solitary fibrous tumours are mesenchymal tumours with an unpredictable progression and current medical treatments for relapsed SFTs remain ineffective. Here, the authors identified potential therapeutic targets and risk factors for SFTs and created an integrated risk model using 101 patients, and validated in 3 independent cohorts to successfully predict tumour progression.